GlassScriptPhysician profile
James C Guarino
NPI 1679572713
$4,991.57
in general payments reported to CMS, 2019-2025
27 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $435 · 2021: $775 · 2022: $809 · 2023: $991 · 2024: $1,010 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $951.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $802.62 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $586.75 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $473.29 | 2019-2024 | Repatha |
| Pfizer INC. | $332.25 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.49 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $198.64 | 2021-2025 | Verquvo |
| Esperion Therapeutics, INC. | $166.61 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $158.69 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Sanofi-Aventis U.S. LLC | $135.68 | 2019-2024 | |
| Boston Scientific Corporation | $132.68 | 2023-2025 | Watchman Access System, Watchman Flx |
| Actelion Pharmaceuticals US, INC. | $119.88 | 2020-2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $118.30 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $79.93 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.04 | 2022-2024 | Lifevest |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $59.94 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $53.34 | 2024 | |
| Heartflow, INC. | $47.69 | 2024 | |
| Daiichi Sankyo INC. | $40.44 | 2023 | Injectafer |
| Novo Nordisk INC | $33.52 | 2023 | Ozempic, Rybelsus |
| Agepha Pharma Fz LLC | $30.89 | 2025 | Lodoco |
| Atricure, INC. | $30.41 | 2023 | |
| Lantheus Medical Imaging, INC. | $27.71 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $27.18 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $23.63 | 2019 | |
| Convatec INC. | $18.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Guarino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.